Unknown PHASE1 INTERVENTIONAL 2-arm NCT03774680

Targeted Polymeric Nanoparticles Loaded With Cetuximab and Decorated With Somatostatin Analogue to Colon Cancer

Polymeric Nanoparticles Loaded With Cetuximab and Decorated With Somatostatin Analogue for Targeting of Colon Cancer

Sponsor: Ahmed A. H. Abdellatif

Conditions Colo-rectal Cancer Colon Cancer

Interventions Cetuximab nanoparticles Oral approved anticancer drug

Updated 7 times since 2019 Last updated: Oct 9, 2019 Started: Feb 1, 2020 Primary completion: Feb 1, 2020 Completion: Jan 11, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03774680, this PHASE1 trial focuses on Colo-rectal Cancer and Colon Cancer and remains ongoing. Sponsored by Ahmed A. H. Abdellatif, it has been updated 7 times since 2020, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE1
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Nov 2021 — Jul 2024 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status
Jan 2021 — Nov 2021 [monthly]

Recruiting PHASE1

▶ Show 2 earlier versions

Nov 2019 — Jan 2021 [monthly]

Recruiting PHASE1
Jan 2019 — Nov 2019 [monthly]

Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ahmed A. H. Abdellatif

Data source: Al-Azhar University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Asyut, Egypt
• Buraidah, Saudi Arabia